Close

Aegis Positive on Synergy Pharma (SGYP); Approved to Move Plecanatide into IBS-C Treatment Phase 3

July 8, 2014 8:59 AM EDT Send to a Friend
Aegis Capital affirms Synergy Pharmaceuticals (Nasdaq: SGYP) at Buy with a target price of $26 following news that the FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login